Clinical Trial

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
Protocol Amendment History 47 amendments
This ClinicalTrials.gov record has been amended 47 times since 2019-12-17; most recent amendment 2025-11-10.
Status change: Enrolling by Invitation → Active, Not Recruiting 2023-10-10
Status change: Recruiting → Enrolling by Invitation 2022-08-15
Status change: Not Yet Recruiting → Recruiting 2021-01-05
Trial Details
NCT Number NCT04204616
Lead Sponsor Galderma R&D
Conditions Prurigo Nodularis
Enrollment 500 participants
Start Date 2021-01-11
Primary Completion 2026-10-26 (estimated)
Study Completion 2026-10-26 (estimated)
Updated on ClinicalTrials.gov 2025-11-12